Literature DB >> 11347720

Lipodystrophy syndrome in patients with HIV infection: quality of life issues.

E Martínez1, M A Garcia-Viejo, L Blanch, J M Gatell.   

Abstract

Current antiretroviral therapy has lead to longer survival in patients infected with HIV, but it is also associated with new and important problems. Body fat redistribution and metabolic abnormalities, the so-called lipodystrophy syndrome, are among the most prevalent and worrisome ones. While an increasing number of patients infected with HIV are becoming affected by this syndrome, the pathogenesis of this syndrome and how to prevent and treat the problem all remain largely unknown. Body fat changes stigmatise the bodies of patients infected with HIV giving them a similar look to that seen in patients some years ago when the wasting syndrome was more prevalent and HIV infection was ultimately fatal. The psychological impact of body fat changes may be severe enough to affect a patients' desire to continue with antiretroviral therapy. Metabolic abnormalities, probably with the exception of symptomatic diabetes mellitus and hypertriglyceridaemia-induced pancreatitis, do not have an immediate impact on the quality of the lives of patients with HIV. However, their potential long term cardiovascular and bone consequences may increase the morbidity and the mortality of patients infected with HIV through noninfectious diseases. The impact of lipodystrophy on patients infected with HIV is not readily captured with the classic instruments used to measure quality of life and hence it is necessary to modify them urgently. Though treating lipodystrophy seems fully justified, there is no proven treatment for this problem, although a number of treatments have been used with varying success. Despite the recognition that lipodystrophy may have important psychological repercussions, the best psychological approach for this problem is not known at present. Although lipodystrophy has its own peculiarities, existing knowledge about how to psychologically help other patients with deforming body changes might be of help for patients infected with HIV, or at least may act as a starting point.

Entities:  

Mesh:

Year:  2001        PMID: 11347720     DOI: 10.2165/00002018-200124030-00001

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  48 in total

Review 1.  Fat distribution and metabolic changes in patients with HIV infection.

Authors:  S Safrin; C Grunfeld
Journal:  AIDS       Date:  1999-12-24       Impact factor: 4.177

2.  The effects of discontinuing stavudine therapy on clinical and metabolic abnormalities in patients suffering from lipodystrophy.

Authors:  T Saint-Marc; J L Touraine
Journal:  AIDS       Date:  1999-10-22       Impact factor: 4.177

3.  Liposuction for protease-inhibitor-associated lipodystrophy.

Authors:  S Ponce-de-Leon; M Iglesias; J Ceballos; L Ostrosky-Zeichner
Journal:  Lancet       Date:  1999-04-10       Impact factor: 79.321

Review 4.  Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance.

Authors:  A Carr; K Samaras; D J Chisholm; D A Cooper
Journal:  Lancet       Date:  1998-06-20       Impact factor: 79.321

5.  Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine.

Authors:  E Martínez; I Conget; L Lozano; R Casamitjana; J M Gatell
Journal:  AIDS       Date:  1999-05-07       Impact factor: 4.177

6.  Performance of a new, HIV/AIDS-targeted quality of life (HAT-QoL) instrument in asymptomatic seropositive individuals.

Authors:  W C Holmes; J A Shea
Journal:  Qual Life Res       Date:  1997-08       Impact factor: 4.147

7.  Use of the MQoL-HIV with asymptomatic HIV-positive patients.

Authors:  K W Smith; N E Avis; K H Mayer; L Swislow
Journal:  Qual Life Res       Date:  1997-08       Impact factor: 4.147

8.  Opportunistic infections occurring during highly active antiretroviral treatment.

Authors:  C Michelet; C Arvieux; C François; J M Besnier; J P Rogez; J P Breux; F Souala; C Allavena; F Raffi; M Garre; F Cartier
Journal:  AIDS       Date:  1998-10-01       Impact factor: 4.177

9.  Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group.

Authors:  A Mocroft; S Vella; T L Benfield; A Chiesi; V Miller; P Gargalianos; A d'Arminio Monforte; I Yust; J N Bruun; A N Phillips; J D Lundgren
Journal:  Lancet       Date:  1998-11-28       Impact factor: 79.321

10.  The effect of protease inhibitors on weight and body composition in HIV-infected patients.

Authors:  M Silva; P R Skolnik; S L Gorbach; D Spiegelman; I B Wilson; M G Fernández-DiFranco; T A Knox
Journal:  AIDS       Date:  1998-09-10       Impact factor: 4.177

View more
  13 in total

1.  Quality of life and body image in the assessment of psychological impact of lipodystrophy: validation of the Italian version of assessment of body change and distress questionnaire.

Authors:  G Guaraldi; G Orlando; R Murri; M Vandelli; M De Paola; B Beghetto; G Nardini; S Ciaffi; F Vichi; A W Wu
Journal:  Qual Life Res       Date:  2006-02       Impact factor: 4.147

2.  The association of self-perception of body fat changes and quality of life in the Women's Interagency HIV Study.

Authors:  Michael Plankey; Peter Bacchetti; Chengshi Jin; Priscilla Dass-Brailsford; Deb Gustafson; Mardge H Cohen; Roksana Karim; Michael Yin; Phyllis C Tien
Journal:  AIDS Care       Date:  2013-05-08

Review 3.  A comparative review of health-related quality-of-life measures for use in HIV/AIDS clinical trials.

Authors:  Darren J Clayson; Diane J Wild; Paul Quarterman; Isabelle Duprat-Lomon; Maria Kubin; Stephen Joel Coons
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

4.  The relationship between lipodystrophy-associated body changes and measures of quality of life and mental health for HIV-positive adults.

Authors:  Robert Burgoyne; Evan Collins; Cheryl Wagner; Susan Abbey; Mark Halman; Margaret Nur; Sharon Walmsley
Journal:  Qual Life Res       Date:  2005-05       Impact factor: 4.147

5.  Prevalence of fat redistribution and metabolic disorders in human immunodeficiency virus-infected children.

Authors:  Ana María Sánchez Torres; Raquel Munoz Muniz; Rosario Madero; Clementina Borque; María Jesús García-Miguel; María Isabel De José Gómez
Journal:  Eur J Pediatr       Date:  2005-01-14       Impact factor: 3.183

6.  Alcohol consumption and lipodystrophy in HIV-infected adults with alcohol problems.

Authors:  Debbie M Cheng; Howard Libman; Carly Bridden; Richard Saitz; Jeffrey H Samet
Journal:  Alcohol       Date:  2009-02       Impact factor: 2.405

7.  A qualitative study of the psychosocial implications of lipodystrophy syndrome on HIV positive individuals.

Authors:  R Power; H L Tate; S M McGill; C Taylor
Journal:  Sex Transm Infect       Date:  2003-04       Impact factor: 3.519

8.  Validation of a specific questionnaire on psychological and social repercussions of the lipodystrophy syndrome in HIV-infected patients.

Authors:  Ana Marín; José L Casado; Lidia Aranzabal; Javier Moya; Antonio Antela; Fernando Dronda; Ana Moreno; Santiago Moreno
Journal:  Qual Life Res       Date:  2006-06       Impact factor: 3.440

9.  A longitudinal evaluation of the impact of a polylactic acid injection therapy on health related quality of life amongst HIV patients treated with anti-retroviral agents under real conditions of use.

Authors:  Martin Duracinsky; Pascale Leclercq; Andrew Richard Armstrong; Marc Dolivo; Frédéric Mouly; Olivier Chassany
Journal:  BMC Infect Dis       Date:  2013-02-20       Impact factor: 3.090

10.  HIV-associated adipose redistribution syndrome (HARS): definition, epidemiology and clinical impact.

Authors:  Kenneth Lichtenstein; Ashok Balasubramanyam; Rajagopal Sekhar; Eric Freedland
Journal:  AIDS Res Ther       Date:  2007-07-16       Impact factor: 2.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.